Press release from Sigma-17

[Samura Heavy Industries]

Samura Heavy Industries and Cryer Pharmaceuticals have recently agreed upon a new contract, which spokesmen say will bring significant wealth to each. After the official signing earlier this afternoon, it was revealed that the following agreements were made:

Cryer agrees to the following:

• Allowing all Samura| tagged vessels to land at their stations, by passing the normal security and going to a non-disclosed background check policy.
  
• To purchase Hydrocarbons and Polymers for use on Planet Denver exclusively from Samura at near-cost.
  
• To purchase Alien Organisms exclusively from Samura for use at Atka Research Station.
  
• To turn over any Kusari criminal captured to the closest Kusari jurisdiction.
  

Samura agrees to the following:

• Allowing all Cryer| vessels to land at their holdings with the same security precautions as above.
  
• To purchase Pharmaceuticals exclusively from Cryer.
  
• To treat Planet Kurile as a tariff-free zone for Cryer Pharmaceuticals and its business partners.
  
• To turn over any cardamine-addicted criminal to Cryer Pharmaceuticals in an attempt to cure them of their habit.
  

Both agree to the following:

• To work toward making Sigma-17 an entirely tariff-free trade zone for both corporations.
  
• To begin an initiative to further research applications for Alien Organisms.
  
• To establish a committee to deal with the increase of piracy in Sigma-17.
  

"Today marks the start of an even greater relationship between our two corporations," Mr Kiyoshi Sato of Samura Heavy Industries said.

"We feel this deal will solidify our position together in the Sigma 17 system and allow us both to thrive and grow in a better environment, and hope our relationship will continue to improve," Mr Timothy Cryer was said.

"A deal like this can only bring success for everyone involved," Mr Hitoshi Fujiyama of Samura was heard as saying.

"I'm certainly looking forward to the future venture in researching these fascinating organisms," Dr Andrew Fredericks, a researcher with Cryer Pharmaceuticals, stated to the press.

---

Overview - Recruitment - Central Communications - Bounty Board -
Xuanming Trade Centre - Feedback - Wiki